Acepodia, Inc. (TPEX:6976)

Market Cap	8.94B
Revenue (ttm)	301.00K
Net Income (ttm)	-655.56M
Shares Out	582.16M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	505,901
Average Volume	635,465
Open	15.25
Previous Close	15.25
Day's Range	15.15 - 15.35
52-Week Range	13.80 - 25.00
Beta	0.87
RSI	47.85
Earnings Date	Mar 19, 2026

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 that is in phase 1 clinical trial. Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shih-Chia Hsiao
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6976

Financial Performance

In 2024, Acepodia's revenue was 427,000, a decrease of -97.43% compared to the previous year's 16.59 million. Losses were -496.75 million, -39.22% less than in 2023.